Antibiotic Resistance: Advancing Infectious Disease Therapeutics for Patients

A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Medication Management".

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 1659

Special Issue Editors


E-Mail Website
Guest Editor
Medication Outcomes Center, University of California San Francisco, San Francisco, CA 94143, USA
Interests: drug safety; Health Services Research; Pharmaceutical economics and policy; Opioid analgesic prescribing patterns; Health economics and outcomes evaluation; Drug shortages; Gambling; Sulfonylurea Compounds; health care costs; Glycoside Hydrolase Inhibitors; Fees and Charges; Drug Costs; Mental Disorders; Patents as Topic; Orphan Drug Production; Drug Approval; United States Food and Drug Administration; Biological Therapy; Dipeptidyl-Peptidase IV Inhibitors; Drugs; Generic; Costs and Cost Analysis

E-Mail Website
Guest Editor
1. Department of Pharmaceutical Economics and Policy Department, School of Pharmacy, Chapman University, Irvine, CA 92618, USA
2. Economic Science Institute, Argyros School of Business and Economics, Chapman University, Orange, CA 92866, USA
Interests: pharmaceutical economics; drug regulation; drug policy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Significance of the proposed special issue:

Over the past four decades, the United States Congress has enacted legislation aimed at providing various incentives to promote the development and regulatory approval of antibiotics. These legislative acts include the Food and Drug Administration Modernization Act (1997), the Generating Antibiotic Incentives Now Act (2012), the Qualified Infectious Disease Product Designation (2012), and the 21st Century Cures Act (2016). The purpose of these incentives was to address the pressing need for more effective treatment options for patients who lacked viable alternatives. In light of the significant public health risk posed by antibiotic resistance and the growing concerns regarding the emergence of multi-resistant bacterial pathogens, there is an urgent need for the discovery and research of novel antibiotics and research in this area. Therefore, this Special Issue will shed light on the effectiveness of US regulatory measures and implemented policies in bringing novel systemic antibiotics to the US market compared to available therapeutic alternatives addressing unmet medical needs for drug-resistant bacteria.

Call for papers for Special Issue on :

Dear Colleagues,

This Special Issue of Healthcare is dedicated to addressing the crucial challenge of developing novel antibiotics that can effectively tackle drug resistance, enhance patient outcomes, and meet unmet medical needs.

Federal regulation enacted since the early 1990s, including the Prescription Drug User Fee Act (1992), the Food and Drug Administration Modernization Act (1997), the Generating Antibiotic Incentives Now Act (2012), and the Qualified Infectious Disease Product Designation (2012), and the 21st Century Cures Act (2016), was aimed at accelerating drug development to bring more efficacious drugs to the US market faster. As antibiotic resistance continues to undermine the effectiveness of antibiotics and concerns surrounding multi-resistant bacterial pathogens intensify, there is a pressing need for robust research on the added value of antibiotics addressing the need for the greater effectiveness of new antibiotics in patients who lack effective options. This Special Issue focuses on exploring the multifaceted factors that have contributed to the existing crisis in the development of novel antibiotics. Furthermore, it aims to provide managers, policymakers, and other stakeholders with up-to-date knowledge and valuable insights into the impact of regulation and policy, clinical practices, and patient-centered outcomes on the development of innovative antibiotics for patients with susceptible and resistant pathogens who lack effective options to enhance their survival, improve functioning, and reduce their symptoms burden.

This Special Issue will consider original articles, with a special focus on issues such as:

  1. Antibiotic resistance;
  2. Regulation and policy in clinical practice;
  3. Standards and evidence for approval of anti-infectives;
  4. Utilization management, empirical use, and appropriate prescribing of antibiotics;
  5. Comparative effectiveness and patient outcomes;
  6. Antibiotics pricing and reimbursement.

All manuscripts submitted to this Special Issue will undergo a rigorous peer-review process.

Dr. Rosa Rodriguez-Monguio
Prof. Dr. Enrique Seoane-Vazquez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibiotic resistance
  • regulation and policy in clinical practice
  • standards and evidence for approval of anti-infectives
  • utilization management, empirical use, and appropriate prescribing of antibiotics
  • comparative effectiveness and patient outcomes
  • antibiotics pricing and reimbursement

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 764 KiB  
Article
Comparing Actual and Rounded Serum Creatinine Concentration for Assessing the Accuracy of Vancomycin Dosing in Elderly Patients: A Single-Center Retrospective Study
by Rawan Bukhari, Hani Hasan, Doaa Aljefri, Rawan Rambo, Ghusun AlSenaini, Yahya A. Alzahrani and Abdullah M. Alzahrani
Healthcare 2024, 12(11), 1144; https://doi.org/10.3390/healthcare12111144 - 4 Jun 2024
Viewed by 1232
Abstract
Prescribers often face the challenge of predicting creatinine clearance (CrCl) in elderly patients who are 65 years or older and have serum creatinine (SCr) concentrations below 1 mg/dL. Studies have shown that utilizing rounded SCr would underestimate CrCl in this population, which could [...] Read more.
Prescribers often face the challenge of predicting creatinine clearance (CrCl) in elderly patients who are 65 years or older and have serum creatinine (SCr) concentrations below 1 mg/dL. Studies have shown that utilizing rounded SCr would underestimate CrCl in this population, which could lead to the under-dosing of some medications like vancomycin. The current study aimed to compare the accuracy of vancomycin dosing using actual SCr versus rounded SCr to 1 mg/dL in elderly patients. A total of 245 patients were included. The therapeutic trough level (10–20 mg/L) was achieved in 138 (56.3%) patients using actual SCr. Sub-therapeutic (<10 mg/L) and supra-therapeutic (>20 mg/L) trough levels were observed in 32 (13.1%) and 75 (30.6%) patients, respectively. The predictive performance of different vancomycin doses based on actual SCr and rounded SCr compared to the targeted maintenance dose (TMD) showed a stronger correlation of dosing based on actual SCr with TMD (r = 0.55 vs. 0.31) compared to rounded SCr dosing; both doses showed similar precision, with ranges of ±552 mg/day for the dosing based on actual SCr and ±691 mg/day for the dosing based on rounded SCr. Furthermore, the dosing based on actual SCr showed a lower error percentage (69%) and a higher accuracy rate (57.6%) within ±10% of the TMD compared to the dosing based on rounded SCr, which had an error percentage of (92.3%) and an accuracy rate of (40%). The prevalence of vancomycin-associated nephrotoxicity (VAN) was seen in 44 (18%) patients. Patients between 75 and 84 years of age, those who were bedridden, and those with vancomycin trough concentrations greater than 20 mg/L had a higher risk of developing VAN. In conclusion, in elderly patients, estimating vancomycin dosing based on actual SCr was more accurate compared to rounded SCr to 1 mg/dL. The efficacy of vancomycin could be negatively affected by rounding up SCr, which could underestimate CrCl and result in the under-dosing of vancomycin. Full article
Show Figures

Figure 1

Back to TopTop